Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nerudia is a specialist nicotine science and product development company focused on harm reduction and next-generation delivery systems. Based in the United Kingdom, the company provides comprehensive services including e-liquid formulation, device engineering, and global regulatory compliance support. Nerudia operates advanced analytical laboratories to ensure product safety and efficacy in the rapidly evolving vaping and nicotine pouch markets. In 2017, the company was acquired by Imperial Brands to serve as an innovation hub for its Fontem Ventures subsidiary. The firm continues to lead research into non-combustible tobacco alternatives and smoking cessation technologies through rigorous scientific testing and intellectual property development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nerudia.